We developed a new, highly sensitive enzymatic method for quantifying creatine in erythrocytes, which comprises creatine amidinohydrolase, sarcosine oxidase, and peroxidase. In the present method, an N-methylcarbamoyl derivative of methylene blue, 10-N-methylcarbamoyl-3,7-bis(dimethylamino)phenothiazine (MCDP), was used as a sensitive chromogenic compound. Potassium ferrocyanide was used to prevent nonspecific oxidation of MCDP. The enzymatic method exhibited good analytical performance: precision, within-run CVs <1.0% and between-day CVs <2.0%; average analytical recovery, 99.3% ؎ 1.8%; detection limit, 1.0 mol/L in hemolysate; and linearity, at least up to 500 mol/L as creatine concentration in hemolysate. Excellent agreement was observed between the present method (y) and HPLC (x), y ‫؍‬ 1.029x ؊ 0.002 mol/g hemoglobin, r ‫؍‬ 0.9998, S yͦx ‫؍‬ 0.053 mol/g hemoglobin (n ‫؍‬ 110). No significant interference was produced by various compounds, including guanidino compounds, amino acids, and reducing materials. The reference intervals (mean ؎ 2 SD) for erythrocyte creatine obtained from 60 males and 60 females were (in mol/g hemoglobin) 1.18 ؎ 0.52 (0.66 -1.70) for males and 1.35 ؎ 0.49 (0.86 -1.84) for females. Using this method, we documented changes in erythrocyte creatine in patients with various hemolytic conditions, including hemolytic anemia, liver cirrhosis, renal insufficiency, and chronic renal failure treated with hemodialysis with or without the administration of erythropoietin. We conclude that the use of MCDP allows sensitive measurement of erythrocyte creatine and that MCDP with potassium ferrocyanide can improve the sensitivity of assays that use peroxidase for detection of H 2 O 2 .
A decrease in the erythrocyte survival time is regarded as an essential diagnostic feature of hemolytic disorders. For determination of the erythrocyte survival time, in vivo labeling of erythrocytes with 51 Cr has been performed as a standard method (1) . However, the 51 Cr-labeling method is not suitable for routine tests in clinical laboratories because it requires exclusive equipment for radioactive materials and a prolonged examination period for a series of blood drawings from patient. The reticulocyte count has also been used as an indirect marker for hemolytic disorders. The number of reticulocytes is known to reflect the rate of erythrocyte production (erythropoiesis) (2) . In practice, however, the number of reticulocytes is influenced by other factors, including the length of the reticulocyte growth time in peripheral blood and the severity of anemia (3) . Thus, it is now known that the reticulocyte count is not a good indicator for the mean age of the erythrocyte population (3) . In addition, the reticulocyte survival time in peripheral blood seems to be too short to detect a slight decrease in the mean age of the erythrocyte population (4, 5) . Other laboratory tests, including ones for hemoglobin, indirect bilirubin, and haptoglobin in serum, are widely used for detection of the presence of hemolytic processes, but these tests are not specific to hemolytic episodes.
In 1967, Griffiths and Fitzpatrick (6) suggested that erythrocyte creatine was a sensitive indicator of the mean age of the erythrocyte population, because young erythrocytes contain at least six-to ninefold higher creatine than old erythrocytes. Opalinski and Beutler (7) also showed that erythrocyte creatine was chiefly related to the mean age of erythrocytes rather than to the degree of anemia. Fehr and Knob (4) demonstrated that the erythrocyte creatine content was closely correlated with the erythrocyte survival time, as measured with the 51 Crlabeling technique, in several hemolytic patients. Thereafter, various applications of erythrocyte creatine were reported: e.g., for efficient detection of erythrocyte en-zyme deficiencies in reticulocytosis (8) , for estimation of neonatal erythrocyte age using cord blood (9) , for monitoring of erythropoiesis in patients after renal transplantation (10) , and for detection of slight hemolysis in longdistance runners (11) .
A colorimetric method based on the diacetyl-␣-naphthol reaction has been widely used for measurement of erythrocyte creatine (4 -12) . The diacetyl-␣-naphthol method, however, exhibits positive interference from various guanidino compounds and amino acids in erythrocytes (e.g., arginine, creatinine, guanidine, and guanidinoacetic acid) (13, 14) , and is not appropriate for automated analyzers commonly used in clinical laboratories because of instability of the reagents (12, 15) . Recently, some enzymatic methods for erythrocyte creatine involving two major principles have been reported: the creatine kinase (CK; EC 2.7.3.2) 5 /pyruvate kinase (PK; EC 2.7.1.40)/lactate dehydrogenase (LDH; EC 1.1.1.27) system (15, 16) , and the creatine amidinohydrolase (CTase; EC 3.5.3.3)/sarcosine oxidase (SOX; EC 1.5.3.1)/peroxidase (POD; EC 1.11.1.7) system (14, 17) . These enzymatic methods are specific to creatine in erythrocytes. The former method, however, has low sensitivity because of the modest molar absorptivity of NADH. Because an erythrocyte sample for creatine measurement must be highly diluted in the process of sample pretreatment for both hemolysis and deproteinization, a much more sensitive enzymatic method is desirable.
In this study, we developed a new, highly sensitive enzymatic method for the measurement of erythrocyte creatine comprising the CTase/SOX/POD system coupled with an N-methylcarbamoyl derivative of methylene blue, 10-N-methylcarbamoyl-3,7-bis(dimethylamino)phenothiazine (MCDP) (18) , as a chromogenic compound. Using this method, we measured erythrocyte creatine in patients with various hemolytic conditions to evaluate its potential for clinical usefulness as an index of the erythrocyte mean age.
Materials and Methods apparatus
We used a UVIDEC-610C spectrophotometer (JASCO) and a COBAS MIRA automatic analyzer (Roche) to establish the optimal conditions for the present method. The COBAS MIRA analyzer was also used for the enzymatic measurement of creatine in erythrocyte samples. HPLC (LC4A/CTO-2A/RF-530; Shimadzu) was performed on an ion-exchange column (ISC-05/S0504, Shimadzu). Hematological examinations, including erythrocyte count, hemoglobin concentration, platelet count, and mean corpuscular hemoglobin concentration in blood samples were carried out with an automated analyzer, Sysmex SE-9000; and reticulocyte counts were performed with an automated analyzer, Sysmex R-3000 (both from TOA Medical Electronics).
enzymes and chemicals
CTase (from Actinobacillus sp.), SOX (from Arthrobactor sp.), and POD (from horseradish) were purchased from Toyobo. Catalase (from bovine liver) was purchased from Sigma Chemical Co. Ascorbate oxidase (from Cucurbita sp.) was purchased from Wako Pure Chemical. The methylene blue derivative, MCDP, which was synthesized by Kyowa Medix, was used as a chromogenic compound. The structure of MCDP (C 18 H 22 N 4 OS; molecular weight, 342.4) is shown in Fig. 1 . Triethylenetetraminehexaacetic acid (TTHA), potassium ferrocyanide, sodium azide, glutathione (reduced and oxidized forms), ascorbate, and various amino acids and guanidino compounds including creatine were obtained from Sigma. Other chemicals used were of reagent grade unless otherwise stated.
reaction principle for the enzymatic method
The principle of the present method can be summarized as follows:
Second reaction:
In the first reaction, endogenous sarcosine is eliminated from a sample with SOX and catalase. In the second 5 Nonstandard abbreviations: CK, creatine kinase; PK, pyruvate kinase; LDH, lactate dehydrogenase; CTase, creatine amidinohydrolase; SOX, sarcosine oxidase; POD, peroxidase; MCDP, 10-N-methylcarbamoyl-3,7-bis (dimethylamino) phenothiazine; HTIB, 3-hydroxy-2,4,6-triiodobenzoic acid; TTHA, triethylenetetraminehexaacetic acid; and RBC, red blood cell. reaction, catalase is completely inhibited with sodium azide, and then creatine present in the sample is detected with the CTase/SOX/POD system coupled with MCDP oxidation (Fig. 1) . The MCDP oxidation yields methylene blue, which leads to an increase in the absorbance at 660 nm in proportion to the creatine concentration.
procedure Pretreatment of specimens. Blood was collected in EDTAcontaining tubes and then subjected to hematological examinations. Each blood sample was centrifuged for 10 min at 1500g to remove the plasma and buffy coat. The erythrocytes were hemolyzed with an approximately sixfold volume of 1.0 g/L saponin and then stored for 10 min at room temperature to accomplish complete hemolysis. Because the amount of creatine in the trapped plasma was negligible because of the low concentration of plasma creatine (approximately one-tenth of that of erythrocyte creatine) (4), the erythrocyte sample was not washed in the above procedure. An aliquot (50 L) of the hemolysate was then mixed with 100 L of 0.15 mol/L Ba(OH) 2 and 100 L of 0.15 mol/L ZnSO 4 for deproteinization. The supernatant, obtained on centrifugation for 5 min at 10 000g and filtration, was used for creatine measurement by both the present method and HPLC. The hemolysate was also subjected to hemoglobin measurement for conversion of the measured creatine value (mol/L in supernatant) to micromoles of creatine per gram of hemoglobin. The two reagents were stored in light-proof bottles at 4°C and could be used for at least 3 weeks.
Reagents and analytical conditions for the present method.
The analytical conditions for erythrocyte creatine on the COBAS MIRA analyzer were as follows: wavelength, 660 nm; temperature, 37°C; sample volume, 30 L (washing H 2 O volume, 20 L); reagent 1 volume, 130 L; reagent 2 volume, 70 L; and calculation mode, endpoint assay with a reagent blank. The timing (25 s per one cycle) for sample and reagent additions was: sample and reagent 1, cycle 1; and reagent 2, cycle 12. The timing for readings was: first, cycle 11; and last, cycle 30. The reaction time after the addition of reagent 2 was 7 min 55 s. As a calibrator for measurement of erythrocyte creatine, we used 100 mol/L creatine dissolved in water, which can be used for at least 1 month when stored at 4°C.
Comparison methods.
To compare the sensitivity of the present method with that of other enzymatic methods for creatine measurement, we measured 0, 25, 50, 75, and 100 mol/L creatine calibrators in triplicate with the present method and two other enzymatic methods (each an endpoint assay system), involving the CK/PK/LDH/ NADH system (16) and the CTase/SOX/POD system coupled with 3-hydroxy-2,4,6-triiodobenzoic acid (HTIB) as a chromogenic compound (17) , respectively, according to previous reports, except that the sample dilution ratio (sample volume/total reaction mixture volume) was 0.12. For the correlation study, HPLC with fluorescence detection based on the alkaline-ninhydrin reaction was performed as described previously (19) with minor modifications (20) .
Optimization of the components for the present method. The optimal concentration (or activity) for each component was investigated by assaying the 100 mol/L creatine calibrator with the analytical conditions described above. The observed absorbance was expressed as relative reactivity in comparison with the maximal absorbance. The optimal activity of catalase for elimination of endogenous sarcosine was also investigated by assaying an aqueous 100 mol/L sarcosine.
Effect of potassium ferrocyanide on the linearity. The effect of potassium ferrocyanide on the linearity of the present method was assessed with 0, 6.25, 12.5, 25, 50, and 100 mol/L creatine calibrators in the presence of various concentrations of potassium ferrocyanide (i.e., the reaction mixture did not contain erythrocyte sample).
Interference. Various substances, including guanidino compounds and amino acids with chemical structures related to that of creatine and reducing agents, were investigated as to their possible interference with creatine measurement by the present method. The creatine concentration was measured in solutions containing 100 mol/L creatine to which each substance (100 mol/L) had been added, and the measured value was examined for the percentage of cross-reactivity, defined as [(the measured value/the value for creatine only) Ϫ 1] ϫ 100.
specimens
To determine the reference intervals, we measured creatine in 120 blood samples obtained from 60 healthy males (age, 40.5 Ϯ 18.9 years; mean Ϯ SD) and 60 healthy females (age, 40.9 Ϯ 19.2 years). One hundred and ten patient blood samples, which were submitted routinely to our laboratory, were used for comparison with HPLC. For clinical evaluation, erythrocyte creatine was measured in Clinical Chemistry 44, No. 7, 1998 various patient groups summarized in Table 1 . These blood samples were stored at 4°C and were subjected to treatment for hemolysis and deproteinization within 3 days. The supernatants were stored at Ϫ20°C until creatine measurement.
These samples were prepared and analyzed in accordance with the ethical recommendations of the hospital's responsible committee.
expression units
The Fig. 2 . The presence of 60 kU/L catalase in the first reaction mixture was sufficient to eliminate 100 mol/L sarcosine in a sample within 4 min 35 s (the time for the first reaction); the catalase was then promptly and completely inhibited by the presence of 5.0 mmol/L sodium azide in the final reaction mixture. However, the creatine assay was not affected by the concentration of sodium azide.
Effect of potassium ferrocyanide on the linearity of the creatine measurement.
The effect of potassium ferrocyanide on the linearity of the present method is shown in Fig. 3 . The presence of 20 mol/L potassium ferrocyanide in the final reaction mixture most efficiently improved the linearity for quantifying creatine.
analytical evaluation
Precision. The within-run imprecision of the present method was estimated by repeated analysis of three different hemolysates containing 76.8, 157.6, and 296.5 mol/L creatine, respectively. The within-run CVs (n ϭ 20 for each hemolysate) were 0.9%, 0.7%, and 0.8%, respectively. To estimate the between-day imprecision, the three hemolysates were stored at Ϫ20°C and then assayed with the present method over 20 days. The between-day CVs (n ϭ 20 for each hemolysate) were 1.5%, 1.3%, and 1.4%, respectively.
Linearity. To examine the linearity of the calibration curve, nine different creatine solutions, ranging from 0 to 100 mol/L in 12.5 mol/L increments, were measured with Because the erythrocyte samples, after the removal of the plasma and buffy coat, were diluted sevenfold or more with 1.0 g/L saponin in the sample pretreatment, the measurable upper limit was estimated to be ϳ11 mol/g Hb, or 3500 mol/L RBCs.
Detection limit. To examine the detection limit of the present method, a creatine free-hemolysate, which was prepared from hemolysate (from a healthy subject) by incubation with 25 kU/L CTase at 37°C for 1 h, was measured 10 times after deproteinization. The detection limit, defined as mean ϩ 3 SD of the measured values, was 1.0 mol/L in hemolysate (ϳ0.02 mol/g Hb, or 7 mol/L RBCs).
Analytical recovery rate. In this experiment, three different hemolysates, to which various concentrations of creatine had been added, were assayed five times, respectively. As shown in Table 2 , the analytical recovery rates varied from 95.5% to 101.4% (mean Ϯ SD, 99.3% Ϯ 1.8%).
Interference. No cross-reactivity (within Ϯ 1.0%) was observed with various substances, including sarcosine, creatinine, creatine phosphate, guanidinoacetic acid, guanidinosuccinic acid, ␥-guanidinobutyric acid, ␤-guanidinopropionic acid, methylguanidine, arginine, arginosuccinic acid, alanine, aspartic acid, ornithine, citrulline, proline, cysteine, tryptophan, methionine, glutathione (reduced and oxidized forms), and ascorbic acid, respectively, each at a concentration of 100 mol/L.
Comparison of the sensitivity of the three enzymatic methods for creatine measurement. As shown Fig. 4 , the present method exhibited higher sensitivity than the other two enzymatic methods. The relative sensitivities (present method ϭ 1.00) were 0.079 for the CK/PK/LDH/NADH method and 0.36 for the CTase/SOX/POD/HTIB method, respectively, as estimated with the slope of the curve.
Correlation between the present method and HPLC. Erythrocyte creatine was measured in 110 different blood samples with the present method (y) and HPLC (x), and the results were estimated by linear regression analysis. Excellent agreement was observed between the two methods (Fig. 5) .
reference intervals for erythrocyte creatine
The results obtained on measuring erythrocyte creatine in both 60 healthy males and 60 healthy females fitted a gaussian distribution, as judged with the coefficients of skewness and kurtosis, respectively. The reference intervals (mean Ϯ 2 SD) were: The values are COBAS MIRA-generated absorbances at 660 nm for the present method (F), at 500 nm for the CTase/SOX/POD/HTIB method (f), and at 340 nm for the CK/PK/LDH/NADH method (OE), respectively. 581) mol/L RBCs for females. The mean value of erythrocyte creatine was compared between males and females, using the two-sample independent-groups t-test. Erythrocyte creatine in the females was slightly but significantly (P Ͻ0.001) higher than that in the males with both expression units.
clinical evaluation
The mean value of erythrocyte creatine was compared between healthy control and patient groups in each gender group, using the two-sample independent-groups t-test (Table 3) . Significantly higher erythrocyte creatine concentrations were observed in patients with hemolytic anemia, liver cirrhosis, and renal insufficiency, and hemodialysis patients, respectively. Hemodialysis patients undergoing erythropoietin therapy showed significantly higher erythrocyte creatine than those not undergoing the therapy. No significant difference in erythrocyte creatine was observed between the renal insufficiency patients and the hemodialysis patients without erythropoietin therapy.
Discussion
In human erythrocytes, there are various cell age-related markers other than creatine, including 2,3-diphosphoglycerate (7, 11) , potassium (21), hemoglobin (21), ATP (21, 22) , and a number of enzymes, e.g., hexokinase (7, 22) , aspartate aminotransferase (7, 23) , glucose-6-phosphate dehydrogenase (21) (22) (23) , cholinesterase (21, 24) , and pyruvate kinase (25) , which change in content with advancing age of the erythrocytes. These markers, however, have various disadvantages for estimating the erythrocyte age: 2,3-Diphosphoglycerate is affected by the severity of anemia (7); potassium, hemoglobin, and ATP are not sensitive enough for quantitative estimation of erythrocyte aging because of minor differences in their contents between young and old cells (21) ; and the erythrocyte enzymes are unstable on sample storage, and the activities are likely to be interfered by other factors, such as possible contamination by the leukocyte and platelet enzymes, and erroneous results because of possible interference by non-cell age-dependent disease processes. On the other hand, erythrocyte creatine is thought to be the most promising marker for the mean age of the erythrocyte population for the reasons we described earlier.
However, only a few methods for erythrocyte creatine have been reported. Recently, we established an enzymatic method for erythrocyte creatine, using a commercially available kit that had been developed for serum and urine creatine, involving the CTase/SOX/POD/HTIB system (17) . This method was postulated to have higher sensitivity for erythrocyte creatine as compared with the CK/PK/LDH/NADH method, because the molar absorptivity of NADH at 340 nm is fivefold higher than that of a HTIB-derived quinone-imine dye at 515 nm. In this study, we further developed a new highly sensitive enzymatic method for erythrocyte creatine comprising the CTase/SOX/POD system coupled with MCDP as a chromogenic compound. MCDP is quite suitable for detection of a very small amount of analytes, because the methylene blue derived from MCDP exhibits higher molar absorptivity (96 ϫ 10 3 L ⅐ mol Ϫ1 ⅐ cm Ϫ1 at 666 nm per mole of H 2 O 2 ) than that of other chromogenic compounds used in assays based on enzymatic reaction coupled with POD, e.g., p-chlorophenol (15.0 ϫ 10 3 at 500 nm), N-ethyl-N-(2-hydroxy-3-sulfopropyl)-3,5-di- 3 at 515 nm). In the course of establishing the assay system, however, there was a serious problem: the MCDP oxidation derived from the enzymatic reaction was not proportional to creatine concentration ( Fig. 3 ; the curve for 0 mol/L potassium ferrocyanide). We sought a substance to eliminate the nonspecific oxidation of MCDP, and found that potassium ferrocyanide inhibited nonspecific oxidation in the enzymatic reaction. Satisfactory linearity was observed in the presence of 20 mol/L potassium ferrocyanide (Fig.  3) . The sensitivity of the present method was 12.7-fold higher than that of the CK/PK/LDH/NADH method and 2.8-fold higher than that of the CTase/SOX/POD/HTIB method, respectively, suggesting that the present method makes it possible to quantify erythrocyte creatine using blood samples taken in a microcapillary for neonatal patients and that MCDP with potassium ferrocyanide can improve the sensitivity of POD-coupled assays. The present method showed good precision, within-run CVs Ͻ1.0%, and between-day CVs Ͻ2.0%, an acceptable analytical recovery rate that averaged 99.3% Ϯ 1.8%, and high specificity. As compared with other methods, this method is not likely to be affected by the sample matrix, because the volume of an erythrocyte sample is minimal in the final reaction mixture. Excellent correlation was also observed between the present method and HPLC. These data indicate that the present method exhibits favorable analytical performance in sensitivity, precision, and accuracy.
Using the present method, we measured erythrocyte creatine in healthy subjects and patients with various hemolytic conditions. In healthy subjects, the mean of the erythrocyte creatine in females was slightly but significantly (P Ͻ0.001) higher than that in males, in agreement with other reports (6, 9, 12, 14, 16, 17) . In patients with hemolytic anemia, extremely increased erythrocyte creatine concentrations were observed, in accordance with previous reports (4 -7, 16) . A significant increase in erythrocyte creatine was also observed in patients with liver cirrhosis, suggesting accelerated hemolysis because of hypersplenism and a possible abnormality of the erythrocyte membrane in cirrhotic patients (26) . For renal anemia, in the patients with renal insufficiency or chronic renal failure undergoing hemodialysis, a significant increase in erythrocyte creatine was observed in accordance with other reports (4, 14, 16) . In addition, hemodialysis patients undergoing erythropoietin therapy showed significantly higher erythrocyte creatine concentrations than those not undergoing the therapy. These findings suggest that renal anemia is caused in part by a shortened erythrocyte survival time and by insufficient erythropoietin production as a result of destruction of the renal mass, and that the administration of erythropoietin compensates for the reduced erythropoiesis and leads to an increase in young erythrocytes (i.e., a decrease in the mean age of erythrocytes). Thus, erythrocyte creatine measurement provides us with useful information for the evaluation of hemolytic processes not only in patients with hemolytic anemia but also in patients with liver and renal disorders.
In conclusion, the present method is highly sensitive and specific to creatine in erythrocytes and has favorable characteristics for routine work in clinical laboratories because of its applicability to commonly used automated analyzers.
